Introduction
The cone dystrophies and cone-rod dystrophies (CORD) are a heterogeneous group of progressive genetically determined retinal disorders, which may be inherited as an autosomal dominant, autosomal recessive, or X-linked trait. 1 They are characterised clinically by a loss of visual acuity, abnormal colour vision, photophobia, and visual field loss. Many will develop macular atrophy. Electroretinography demonstrates generalised cone system dysfunction with either no or mild rod system involvement. 2 The gene 'Guanylate cyclase 2D, membrane (retina-specific)' (GUCY2D, MIM ID*600179) accounts for up to 35% of patients with autosomal dominant cone dystrophy or CORD. [3] [4] [5] It was also the first gene to be implicated in Leber congenital amaurosis, a major cause of blindness in children. 6 The protein translated by GUCY2D, retinal guanylate cyclase 1, is expressed in both rod and cone photoreceptors. 7 Two mutation sites in GUCY2D, the codons 575 and 838, have been reported to cause autosomal dominant cone dystrophy or CORD. 5, 8 Recently, the mutation p.V933A was described in GUCY2D associated with the phenotype of autosomal dominant central areolar choroidal dystrophy, a condition similar to CORD. 9 The importance of identifying this condition is paramount as, using a gene therapy technique, a partial restoration of visual function has been demonstrated in a GUCY2D knockout mouse model increasing the likelihood of eventual treatment in humans. 10 The present report describes a family with autosomal dominant cone dystrophy due to a de novo mutation in the codon 838 in the GUCY2D gene.
Materials and methods
The study adhered to the tenets of the Declaration of Helsinki. The family were presented to the inherited eye disease clinic at the Moorfields Eye Hospital NHS Foundation Trust, London, UK. All subjects provided informed consent to participate in the study.
Clinical investigations
All participants underwent routine clinical examination, including best-corrected visual acuity, slit-lamp examination, applanation tonometry, and fundoscopy. Colour fundus photographs were obtained using a Topcon TRC 50IA retinal camera (Topcon Corporation, Tokyo, Japan). Fundus autofluorescence imaging (AF) and optical coherence tomography (OCT) were performed using a Spectralis Spectral-domain OCT (Heidelberg Engineering, Heidelberg, Germany). Electrophysiological assessment was performed in the three affected patients using techniques that incorporated the ISCEV standards. 11, 12 Additional On-Off ERGs were performed using an orange stimulus (560 cd/m 2 , duration 200 ms) superimposed on a constant green background (150 cd/m 2 ). S-cone ERGs were performed using a blue stimulus (445 nm, duration 5 ms, 80 cd/m 2 ) superimposed on a constant orange background (620 nm, 560 cd/m 2 ). 13 
Psychophysics
The psychophysical measurements were made using a Maxwellian-view optical system. Wavelengths were selected with interference filters with full-width at half-maximum bandwidths of between 7 and 11 nm (Ealing, South Natick, MA, USA or Oriel, Stratford, CT, USA). The radiance of each beam could be controlled by the insertion of fixed neutral density filters (Oriel) or by the rotation of circular, variable neutral density filters (Rolyn Optics, Covina, CA, USA). Sinusoidal (flicker) modulation was produced by the pulse-width modulation of fast, liquid crystal light shutters (Displaytech, Longmont, CO, USA) at a carrier frequency of 400 Hz (which is much too fast to be visually resolved). In these experiments, the targets were flickered at 92% modulation, the maximum modulation that could be produced with these shutters. The position of the observer's head was maintained by a dental wax impression. The system is described in more detail elsewhere. 14, 15 A flickering target of 41 of visual angle in diameter was presented in the centre of a 91 diameter background field in all experiments. Fixation was central. Each datum point for the individual measurements represents the average of at least three settings. For the L-cone critical flicker fusion measurements (c.f.f.), the wavelength of the target was fixed at 650 nm and its radiance varied from 6.5 to 11.0 log10 quanta/s/degree 2 in steps of about 0.3 log10 units. The target was superimposed upon the centre of a 481 nm background that delivered 8.29 log 10 quanta/s/degree 2 at the cornea. This background mainly served to suppress the rods, but also selectively desensitised the M-cones at lower target radiances. These conditions isolate the L-cone response in the normal observer over most of the 650 nm intensity range, but at high intensities the M-cones may also contribute to flicker detection. Observers adjusted the flicker frequency to find the frequency at which the flicker just disappeared (the so called critical flicker fusion).
Molecular genetics
The GUCY2D gene was screened for disease-causing mutations after extracting the genomic DNA from peripheral blood leukocytes (Nucleon BACC2 kit; GE Healthcare, Little Chalfont, UK). Primers were designed to amplify the coding region and the intronexon boundaries of 20 published exons (NM_000180.3). PCRs were performed using the standard protocols, and the PCR products were analysed and purified. Bi-directional Sanger sequencing of the PCR products was performed using BigDye v3.1 (BigDye Terminator sequencing Cycle Sequencing Ready Reaction kit version 1.1) on a 3730 genetic analyzer (Applied Biosystems (ABI), Warrington, UK). DNAStar sequencing analysis software (Lasergene v8.0, DNA Star Inc., Madison, WI, USA) was used to compare electropherograms with those from control samples.
Four microsatellite markers (D17S1828, D17S1876, D17S1791, and D17S799) were used to determine the haplotypes of a 9.4-Mb region in chromosome 17p surrounding the GUCY2D gene. A multiplex PCR was performed according to the manufacturer's instructions (Applied Biosystems (ABI)), and the pooled amplified products were genotyped using a 3730 genetic analyzer (Applied Biosystems (ABI)). The electropherograms were analysed using the GeneMapper Software version 4.0 (Applied Biosystems (ABI)).
We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this research.
Results

Clinical phenotype
The clinical data on the subjects are summarised in Table 1 and illustrated in Figure 1 .
The earliest symptom experienced by the affected subjects was reduced central vision. The youngest subject (21-year old) noticed deterioration of her visual acuity at 11 years of age. There was a discordance in onset of symptoms in the monozygotic twins (44-year old) with III:3 noticing problems a decade earlier than III:2. Later in the disorder, photoaversion and a difficulty in colour vision developed. No subject reported nyctalopia. The best-corrected visual acuity of subject IV:1 was 6/18 while vision was less than 6/60 in subjects III:2 and III:3. The reduction of vision in the right eye of subject II:1 was from an advanced cataract. He had undergone retinal reattachment surgery in his left eye. Visual acuity was normal in subject II:2. Colour vision (Ishihara) was very poor in subjects III:2, III:3, and IV:1.
Fundus examination of IV:1 showed mild pigmentary changes in the macula. The fundi of the monozygotic twins showed symmetrical well-demarcated perifoveal retinal thinning. The retina of the right eye of II:1 was difficult to examine due to dense cataract. The left eye showed peripapillary atrophy and an abnormal foveal reflex. Subject II:2 showed no abnormality on fundus examination.
Fundus AF of IV:1 showed a small area of mild hypo-autofluorescence in the perifoveal region surrounded by a ring of hyper-autofluorescence. There was progressive decrease in the foveal autofluorescence with age (not shown). Subjects III:2 and III:3 both show a larger central area of speckled hypo-autofluorescence, reflecting patchy atrophic changes in the retinal pigment epithelium (RPE), surrounded by a ring of increased autofluorescence. Subject II:2 had normal AF. FAF could not be performed reliably in II:1 due to cataracts.
OCT was performed in subject IV:1, aged 21 years, and showed abrupt disruption of the inner-outer segment junction layer in the subfoveal photoreceptors. In her mother and aunt (III:2 and III:3), there is thinning of the inner retina with irregular disruption of photoreceptor-RPE complex. The junction between normal and abnormal outer retina corresponded to the hyper-autofluorescent ring referred to above. The OCT was within normal limits in II:2 and was not performed in II:1.
In one of the monozygotic twins III:2, the areas of speckled hypo-autofluorescence were 6.99 and 6.33 mm 2 in the right and left eye, respectively, while in case of her twin sister the areas were 6.89 and 6.83 mm 2 in the right and left eye, respectively. The b-wave amplitudes of photopic cone ERG in III:2 was 65% on the right and 75% on the left eye in comparison to the lower limit of normal while the amplitudes were 68 and 72% of the lower limit of normal on the right and left eye, respectively, in her monozygotic twin III:3.
Functional phenotype
Dark-adapted full-field ERGs (DA 0.01, DA11.0) were normal in III:2, III:3, and IV:1, in keeping with preserved rod system function (Figure 2a) . Photopic 30 Hz flicker ERGs (LA 3.0 30 Hz) showed mild delay (1-4 ms above the upper limit of normal) and amplitude reduction. Single flash cone ERGs (LA 3.0 2 Hz) showed borderline delay with a subnormal b-wave:a-wave ratio in all subjects, suggesting generalised system dysfunction at an inner retinal level. This was confirmed by On-Off 
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ERGs, which showed electronegative On-responses (reduced b-waves); Off-response d-waves were of borderline timing and, although of normal amplitude, showed an abnormal positive 'plateau' following the d-wave. S-cone ERGs were markedly subnormal. Pattern ERGs were undetectable in all the three cases in keeping with severe macular involvement (data not shown).
Psychophysical examination of the cone system was performed in the 21-year-old female (IV:1). L-cone c.f.f. was measured as a function of the radiance of a 650 nm target superimposed in the center of a 480 nm background of 8.26 log 10 quanta/s/degree 2 . Figure 2b shows the c.f.f. results for the left eye of the affected female (gray hexagons). For comparison, the mean data for 12 normal observers are also shown (black squares). With increasing target radiance, the normal L-cone c.f.f. function starts to rise just above 6.5 log 10 quanta/ sec//degree 2 and then continues to rise steadily until reaching a plateau at 43 Hz (see also, eg, Hecht and Shlaer 16 and Hecht and Verrijp 17 ). The affected female shows a devastating loss of L-cone (and M-cone) mediated sensitivity; the target had to be set to almost 100 times brighter than for normal observers for the affected observer to first see flicker, and the c.f.f. reached only 7 Hz.
Molecular genetics
Sanger sequencing of the GUCY2D gene was performed in all the five subjects. Three out of the five (IV:1, III:2, and III:3) carried heterozygous mutation c.2513G4A, p.R838H. The parents (II:1 and II:2) did not carry the mutation. Microsatellite markers surrounding the GUCY2D gene showed that the mutation segregated with the markers derived from the mother (II:2) (Figure 3) .
Discussion
This study describes the detailed phenotype of patients suffering from autosomal dominant cone dystrophy consequent upon a de novo mutation in GUCY2D, reports the first de novo mutation in the gene, compares the phenotype in the monozygotic twins, and expands our knowledge of the clinical, electrophysiological, and psychophysical phenotypes of the disorder.
Onset of the disease as evidenced by a decrease in the visual acuity was variable between early teens to early twenties. There was relative concordance among the monozygotic twins when the areas of speckled hypofluorescence and the b-wave amplitudes of the photopic cone ERG were compared. However, there was a discordance of onset between the two monozygotic twins of more than a decade although the final visual acuity was similar at 44 years of age. Similar variability in the age on onset has been described in patients with CORD consequent upon GUCY2D mutations. [18] [19] [20] [21] All three affected patients in our family had generalised cone dysfunction with severe macular involvement, but unlike the majority of previous cases, [18] [19] [20] [21] there was no ERG evidence of rod system dysfunction. The possibility that rod dysfunction will develop later in life cannot be excluded, but there is no evidence of scotopic ERG reduction with increasing age in this small cohort. An electronegative dark-adapted ERG (b:a ratioo1.0) has been reported in GUCY2D CORD, 18 but in our family, only the light-adapted ERG had a low b:a ratio. The combination of a flicker ERG delay, an electronegative On-response and the unusual shape of the Off-ERG waveform distinguishes these cases from those with autosomal dominant cone dystrophy due to GUCA1A mutation, often associated with a reduced cone ERG of normal timing with subnormal On-and Off-ERG components. 20 The latter study speculated that these abnormalities could result from impaired transduction kinetics, but there is also evidence of weak RetGC expression in the outer plexiform layer 22 and histological evidence of synaptic disruption in cases of CORD. 23 Generalised cone dysfunction was accompanied by perifoveal photoreceptor-RPE disruption in the monozygotic twins. This structural loss of the central cones may result from the high cone density.
In the phototransduction cascade, exposure to a photon results in a decrease in the photoreceptor intracellular Ca 2 þ concentration. This is because light leads to sequential isomerisation of rhodopsin and activation of transducin and phosphodiesterase (PDE). PDE hydrolyses cGMP closing cGMP-gated cation channels ceasing the calcium influx. RetGC-1, the protein translated by GUCY2D is involved in the regeneration of cGMP in the photoreceptors. This is achieved in response to lowering of Ca 2 þ concentration under the influence of guanylate cyclase activating proteins (GCAP). The mutation in this report, p.R838H, is believed to cause a gain of function increasing the affinity of RetGC-1 for GCAP even in high Ca 2 þ concentrations. 24 The cone photoreceptor death in this disorder is believed to be caused by the high cGMP concentration keeping cGMPgated cation channels open, resulting in increased Ca 2 þ concentration in the cell. 25 Decreasing the cGMP concentration may be therapeutic for these individuals. This can potentially be achieved by increasing photopic exposure of the photoreceptors resulting in stimulation of PDE 26 or can be directly achieved by administration of PDE agonists. Interestingly, PDE6C recessive mutations abrogating the PDE function have been described to cause a phenotype of early-onset cone photoreceptor dystrophy. 27 Haplotype analysis of our family confirmed a de novo mutation in GUCY2D transmitted from the unaffected mother. However, de novo mutations more commonly derive from the paternal germline. 28 Ascertainment of a family showing a de novo mutation in any inherited disease affects the counselling advice given to a person presenting with the disorder. The diagnosis of the disorder in an individual without a family history would usually suggest a recessive inheritance. The recurrence risk to future siblings in such a pedigree is extremely low but might occur if the de novo mutation involved the parent's germ-cells, the so called germline mosaicism. However, to date, there have been no reports of this occurring for genes involved in retinal degeneration. Given the findings in this family, the possibility of a de novo mutation causing a dominant allele in GUCY2D needs to be considered as this would dramatically change the risks of recurrence in children from a population risk to 50%. The prevalence of families presenting this way is not known but will become clearer with the implementation of high-throughput sequencing. Alternatively, in cone dystrophy, specific tests for dominant alleles in GUCY2D and/or GUCA1A should be considered when seeking a molecular diagnosis even in the absence of a family history.
To conclude, this report expands and refines the phenotypic description of patients with the cone dystrophy associated with mutations in GUCY2D gene. The existence of a de novo germline mutation herein described should alert the physician to its possibility in a family with cone dystrophy and has implications for counselling.
Summary
What was known before K Specific alleles of the GUCY2D gene are known to cause autosomal dominant cone dystrophy. De novo mutations have not previously been described in this gene.
What this study adds
K Autosomal dominant cone dystrophy due to GUCY2D can occur without a history in the antecedents due to a de novo mutation. This is important to consider in any simplex case with a similar phenotype. The phenotype description of this disorder is expanded with detailed description of the OCT findings. This paper describes the concordance of the phenotypic findings in the monozygotic twins.
